Swiss National Bank cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 575,300 shares of the medical equipment provider's stock after selling 35,400 shares during the period. Swiss National Bank owned 0.29% of Zimmer Biomet worth $60,769,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Atria Investments Inc grew its stake in shares of Zimmer Biomet by 60.2% during the third quarter. Atria Investments Inc now owns 5,429 shares of the medical equipment provider's stock valued at $586,000 after buying an additional 2,041 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in Zimmer Biomet by 8.6% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 24,995 shares of the medical equipment provider's stock valued at $2,698,000 after acquiring an additional 1,977 shares in the last quarter. KBC Group NV lifted its holdings in shares of Zimmer Biomet by 64.0% during the 3rd quarter. KBC Group NV now owns 25,287 shares of the medical equipment provider's stock valued at $2,730,000 after purchasing an additional 9,864 shares during the last quarter. Metis Global Partners LLC lifted its holdings in shares of Zimmer Biomet by 6.0% during the 3rd quarter. Metis Global Partners LLC now owns 11,885 shares of the medical equipment provider's stock valued at $1,283,000 after purchasing an additional 671 shares during the last quarter. Finally, CIBC Asset Management Inc raised its stake in Zimmer Biomet by 7.4% in the 3rd quarter. CIBC Asset Management Inc now owns 29,718 shares of the medical equipment provider's stock worth $3,208,000 after acquiring an additional 2,039 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Zimmer Biomet
In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.95% of the stock is currently owned by insiders.
Zimmer Biomet Stock Up 0.0 %
Shares of NYSE:ZBH traded up $0.03 during trading on Wednesday, hitting $112.91. The company's stock had a trading volume of 1,919,909 shares, compared to its average volume of 1,933,125. The business has a 50 day moving average price of $106.18 and a two-hundred day moving average price of $106.88. The company has a market capitalization of $22.48 billion, a PE ratio of 25.37, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet's payout ratio is currently 21.57%.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on ZBH. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reissued a "hold" rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Finally, Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus target price of $124.15.
Check Out Our Latest Stock Report on ZBH
Zimmer Biomet Company Profile
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
See Also
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
